Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.
暂无分享,去创建一个
H. Yamazaki | M. Foroozesh | T. Shimada | F. Guengerich | Katsuhiro Tanaka | M. Komori | N. Murayama | S. Takenaka | Martha V. Martin
[1] Ruth Nussinov,et al. Theoretical Characterization of Substrate Access/Exit Channels in the Human Cytochrome P450 3A4 Enzyme: Involvement of Phenylalanine Residues in the Gating Mechanism , 2009, The journal of physical chemistry. B.
[2] Hiroshi Yamazaki,et al. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. , 2009, Chemical research in toxicology.
[3] K. Nishiguchi,et al. The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. , 2009, Biological & pharmaceutical bulletin.
[4] Ying Wang,et al. Mechanism of CYP2C9 Inhibition by Flavones and Flavonols , 2009, Drug Metabolism and Disposition.
[5] H. Yamazaki,et al. Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. , 2008, Chemical research in toxicology.
[6] H. Yamazaki,et al. Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. , 2008, Drug metabolism letters.
[7] J. Arct,et al. Flavonoids as components of biologically active cosmeceuticals. , 2008, Clinics in dermatology.
[8] H. Yamazaki,et al. Heterotropic cooperativity in oxidation mediated by cytochrome p450. , 2008, Current drug metabolism.
[9] Anup A. Kale,et al. Cancer phytotherapeutics: role for flavonoids at the cellular level , 2008, Phytotherapy research : PTR.
[10] M. Foroozesh,et al. Methoxyflavone Inhibitors of Cytochrome P450 , 2008 .
[11] P. Ruzza,et al. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. , 2008, Biochemical pharmacology.
[12] T. Walle,et al. Bioavailable Flavonoids: Cytochrome P450-Mediated Metabolism of Methoxyflavones , 2007, Drug Metabolism and Disposition.
[13] T. Walle. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? , 2007, Seminars in cancer biology.
[14] C David Stout,et al. Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2*♦ , 2007, Journal of Biological Chemistry.
[15] T. Walle,et al. Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones. , 2007, Biochemical pharmacology.
[16] H. Yamazaki,et al. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. , 2007, Chemical research in toxicology.
[17] T. Sjögren,et al. Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.
[18] T. Shimada,et al. Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 , 2006, Molecular Pharmacology.
[19] F Peter Guengerich,et al. Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4* , 2006, Journal of Biological Chemistry.
[20] Gordon C K Roberts,et al. IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER , 2006, Drug Metabolism and Disposition.
[21] Y. Moon,et al. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.
[22] M. Foroozesh,et al. Naphthoflavone propargyl ether inhibitors of cytochrome P450 , 2006 .
[23] T. Shimada,et al. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons. , 2006, Chemical research in toxicology.
[24] Young In Park,et al. Effects of hydroxyl group numbers on the B-ring of 5,7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes , 2005, Archives of pharmacal research.
[25] Shuzhong Zhang,et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. , 2005, Biochemical pharmacology.
[26] F. Guengerich,et al. Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps* , 2005, Journal of Biological Chemistry.
[27] W. Tolleson,et al. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). , 2004, Journal of agricultural and food chemistry.
[28] Eric F. Johnson,et al. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.
[29] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[30] M. Hata,et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. , 2003, Biochemistry.
[31] T. Shimada,et al. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. , 2003, Mutation research.
[32] E. Offord,et al. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[33] H. Yamazaki,et al. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. , 2002, Protein expression and purification.
[34] Thomas Walle,et al. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[35] M. Stiborová,et al. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. , 2002, Chemico-biological interactions.
[36] M. Burke,et al. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. , 2000, Toxicology.
[37] S. Zhai,et al. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[38] K Chiba,et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. , 1998, Biochemical pharmacology.
[39] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[40] T. Shimada,et al. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. , 1989, Cancer research.
[41] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.
[42] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[43] Hideyuki Ito,et al. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[44] W. Baird,et al. Urban dust particulate matter alters PAH-induced carcinogenesis by inhibition of CYP1A1 and CYP1B1. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[45] Tsutomu Shimada,et al. Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. , 2006, Drug metabolism and pharmacokinetics.
[46] F. Guengerich,et al. Human cytochrome P-450 enzymes. , 1992, Life sciences.